SAR 405838
Alternative Names: MI-773; SAR-405838Latest Information Update: 24 Oct 2021
At a glance
- Originator University of Michigan
- Developer Sanofi
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 05 Mar 2018 Sanofi completes a phase I trial in Solid-tumours and Lymphoma in France, Netherlands, USA (NCT01636479)
- 18 May 2016 Chemical structure information added
- 31 May 2015 Discontinued - Phase-I for Lymphoma and Solid tumours in Netherlands (PO)